$ERNA

Ernexa Therapeutics said an independent study reproduced prior UT Anderson Cancer Center results for its ERNA-101 cell therapy, showing complete tumor clearance and durable long-term survival in a larger cohort. The company reported 10 of 15 animals (67%) cleared tumors with ERNA-101 plus anti-PD-1, while other groups had none. Ernexa targets an IND in Q3 2026 and a phase 1 trial in Q4 2026; shares rose 7.43% to $6.51.

Ernexa Therapeutics (Nasdaq: ERNA) said an independent CRO reproduced preclinical results for ERNA-101 plus anti-PD-1 in an ovarian cancer model. In 15 treated animals, 10 (67%) had complete tumor clearance and durable long-term survival, while no complete responses occurred in ERNA-101, anti-PD-1, or control arms. The company plans an IND in Q3 2026 and Phase 1 in Q4 2026.

Ernexa Therapeutics (NASDAQ:ERNA) shares rose 30% after independent preclinical validation of its lead cell therapy ERNA-101 in ovarian cancer models. According to the company, an independent CRO reproduced earlier results, with ERNA-101 plus anti-PD-1 achieving complete tumor clearance and long-term survival in 10 of 15 animals. The company plans an IND submission in Q3 2026 and Phase 1 in Q4 2026.

Ernexa Therapeutics Inc. (ERNA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 ERNEXA THERAPEUTICS INC. 2026 OMNIBUS EQUITY INCENTIVE PLAN TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. De

Ernexa Therapeutics Inc. (ERNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000748592 0000748592 2026-06-22 2026-06-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Ernexa Therapeutics (Nasdaq: ERNA) said manufacturing and IND-enabling work for its lead oncology candidate ERNA-101 is progressing. The company reported GMP production underway and expects an IND submission in Q3 2026, with a Phase 1 first-in-human study planned for Q4 2026. Ernexa also cited preclinical results with PD-1 blockade and completed a $10.5 million financing.

Ernexa Therapeutics (Nasdaq: ERNA) said it has completed process development for ERNA-101 and transitioned toward GMP manufacturing, while technology transfer activities are underway. The company expects to file an IND for ERNA-101 in Q3 2026, enabling a planned first-in-human study.

CAMBRIDGE, Mass., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Ernexa Therapeutics ( NASDAQ:ERNA ) , an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global's premier event, being held ...

The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer ( PROC ) , ...

CAMBRIDGE, Mass., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Ernexa Therapeutics ( NASDAQ: ERNA ) , developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel ...